Incorporating patient-reported outcomes into hepatitis c virus treatment studies

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages 1360-1362

  Evon, Donna M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SOFOSBUVIR; INTERFERON; URIDINE PHOSPHATE;

ANTIVIRAL THERAPY; ANXIETY; DECISION MAKING; DEPRESSION; EDITORIAL; FATIGUE; FUNCTIONAL STATUS; HEPATITIS C; LIVER CIRRHOSIS; MENTAL DISEASE; MORTALITY; PATIENT REPORTED OUTCOME; PATIENT SATISFACTION; PHYSICAL DISEASE; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BEHAVIOR; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; FOLLOW UP; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C VIRUS; HUMAN; LONGITUDINAL STUDY; MEDICAL INFORMATION; MENTAL HEALTH; MOTIVATION; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERSONAL EXPERIENCE; PILOT STUDY; PRODUCTIVITY; QUESTIONNAIRE; STIGMA; WELLBEING; ANALOGS AND DERIVATIVES; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; URIDINE MONOPHOSPHATE;

EID: 84904399630     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.017     Document Type: Editorial

References (14)

1. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims.2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
2. Ahmed S., Berzon R.A., Revicki D.A., et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care 2012, 50:1060-1070.
3. Land S.R., Wickerham D.L., Costantino J.P., et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2742-2751.
4. Younossi Z.M., Stepanova M., Henry L., et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014, 12:1349-1359.
5. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEngl J Med 2013, 368:1867-1877.
6. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEngl J Med 2013, 368:1878-1887.
7. Chou R., Bougatsos C., Blazina I., et al. Treatment of hepatitis C virus infection in adults: future research needs. Future research needs paper no. 28. (Prepared by the Oregon Evidence-based Practice Center under contract no. 290-2007-10057-I), no. 13-EHC021-EF 2013, Agency for Healthcare Research and Quality, Rockville, MD.
8. Drenth J.P. HCV treatment-no more room for interferonologists?. NEngl J Med 2013, 368:1931-1932.
9. Hopwood M. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study. Psychol Health Med 2013, 18:742-750.
10. Anderson R.T., Baran R.W., Erickson P., et al. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res 2014, 23:877-886.
11. Kleinman L., Mannix S., Yuan Y., et al. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes 2012, 10:92.
12. Basch E., Abernethy A.P., Mullins C.D., et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. JClin Oncol 2012, 30:4249-4255.
13. Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 2014, 65:307-317.
14. Lipscomb J., Reeve B.B., Clauser S.B., et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. JClin Oncol 2007, 25:5133-5140.